Advancing iOWH032: Novel Antisecretory Drug for the Treatment of Cholera
PATH and partners are developing iOWH032 as a complement to oral rehydration solution for diarrheal disease treatment. Acting via inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel, iOWH032 is a novel, low-molecular-weight compound intended to reduce fluid and electrolyte loss in cases of cholera toxin-induced secretory diarrhea.
Publication date: August 2017
Advancing iOWH032: Novel Antisecretory Drug for the Treatment of Cholera- PDF
Hard copies are not available.